-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40

Benzinga·11/05/2026 20:42:32
Listen to the news
TD Cowen analyst Tyler Van Buren maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $40.